Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes
Authors
Keywords
Breast cancer, Human epidermal growth factor receptor 2, Fluorescence in situ hybridization, Human epidermal growth factor receptor 2/centromere chromosome probe 17 ratio, Gene copy number
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 150, Issue 3, Pages 581-588
Publisher
Springer Nature
Online
2015-04-03
DOI
10.1007/s10549-015-3334-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HER2 in Breast Cancer
- (2014) Uma Krishnamurti et al. ADVANCES IN ANATOMIC PATHOLOGY
- Current and future role of neoadjuvant therapy for breast cancer
- (2014) Michael Untch et al. BREAST
- Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network
- (2014) A Borley et al. BRITISH JOURNAL OF CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Level of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapy
- (2013) Giuseppe Gullo et al. BREAST
- Breast cancer statistics, 2013
- (2013) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A systematic review of dual targeting in HER2-positive breast cancer
- (2013) Iben Kümler et al. CANCER TREATMENT REVIEWS
- High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting
- (2013) Eva-Maria Fuchs et al. INTERNATIONAL JOURNAL OF CANCER
- Level ofHER2Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab
- (2013) Carlos Gomez-Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues
- (2013) Anna Sapino et al. Frontiers in Oncology
- Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
- (2012) Sally Doss et al. LANCET ONCOLOGY
- Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
- (2012) Hyesil Seol et al. MODERN PATHOLOGY
- Association of HER-2 Copy Number and HER-2/CEP-17 Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast Cancer
- (2012) K.-D. Yu et al. ONCOLOGIST
- Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
- (2011) M. Bates et al. ANNALS OF ONCOLOGY
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
- (2011) Angelo Di Leo et al. LANCET ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
- (2010) S Guiu et al. BRITISH JOURNAL OF CANCER
- Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
- (2010) Allan Lipton et al. CANCER
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
- (2008) Giuseppe Gullo et al. INVESTIGATIONAL NEW DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started